Coherus Oncology Financials - Benzinga

Coherus Oncology Inc

CHRSNASDAQ

Trade with Public

Trade with Public

$1.41

-0.05-3.42%

At close: Aug 28, 5:00 PM EST

$1.39

-0.02-1.42%

After Hours: Aug 28, 6:57 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Coherus Oncology Financials

Coherus Oncology (CHRS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Coherus BioSciences Q2 Adj. EPS $(0.19) Beats $(0.20) Estimate, Sales $14.307M Miss $14.400M Estimate

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 44.12 percent increase over losses of $(0.34) per share from

Benzinga Newsdesk

PRO
Coherus BioSciences Q1 Adj. EPS $(0.25) Beats $(0.27) Estimate, Sales $12.310M Miss $14.342M Estimate

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 28.57 percent increase over losses of $(0.35) per share

Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

Insights into Coherus Oncology Q4 Earnings

Benzinga Insights

PRO
Coherus BioSciences Q4 Adj. EPS $(0.34), Inline, Sales $12.748M Miss $13.944M Estimate

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of

Benzinga Newsdesk

Earnings Scheduled For March 9, 2026

Benzinga Insights